| Dr Ellen Ruth Sher, MD | |
|
802 W Park Ave, Suite 213, Ocean, NJ 07712-8527 | |
| (732) 695-2555 | |
| (732) 695-2552 |
| Full Name | Dr Ellen Ruth Sher |
|---|---|
| Gender | Female |
| Speciality | Allergy/immunology |
| Experience | 38 Years |
| Location | 802 W Park Ave, Ocean, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710961602 | NPI | - | NPPES |
| 6088902 | Medicaid | NJ | |
| 036075ZKRP | Other | NJ | MEDICARE PTAN |
| 036075ZVF5 | Other | NJ | MEDICARE PTAN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207K00000X | Allergy & Immunology | MD59455 (New Jersey) | Secondary |
| 207K00000X | Allergy & Immunology | 25MA05945500 (New Jersey) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Allergy Partners Of Nj Pc | 3274855499 | 8 |
News Archive
Fred Hutchinson Cancer Research Center announced its first-ever grants from its newly established Evergreen Fund to spur researchers' efforts to advance bold ideas toward creating or partnering with a commercial entity.
Iroko Cardio International Sàrl announces long-term, three-year, mortality data from the Phase III, open label, multi-national study comparing high-dose bolus (HDB) dosing of AGGRASTAT(tirofiban) (25mcg/kg bolus followed by a 0.15mcg/kg/min infusion for 18-24 hours) vs. ReoPro (abciximab) in patients undergoing primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI), presented at the 2010 European Society of Cardiology Meeting in Stockholm, Sweden.
A metabolic imbalance in some cancer patients following treatment with a checkpoint inhibitor drug, nivolumab, is associated with resistance to the immunotherapy agent and shorter survival, report scientists from Dana-Farber Cancer Institute, in collaborative work with the Broad Institute of MIT and Harvard.
Mice exposed to stress in the womb and soon after birth can expect a lifetime of immune system deficiencies that hinder the ability to ward off infections and cancer, Yale University researchers report March 5 in the journal Cell.
Novartis announced today new results for Cosentyx® (secukinumab) showing no further progression in joint damage in 84% of patients with psoriatic arthritis (PsA). In addition, Cosentyx maintained a treatment response in joint and skin disease, physical function and quality of life in patients over two years of treatment. These results from the extension phase of the FUTURE 1 study were presented at the 2015 Annual Meeting of the American College of Rheumatology (ACR) in San Francisco, United States.
› Verified 2 days ago
| Entity Name | Allergy Partners Of Nj Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467878405 PECOS PAC ID: 3274855499 Enrollment ID: O20141125000955 |
News Archive
Fred Hutchinson Cancer Research Center announced its first-ever grants from its newly established Evergreen Fund to spur researchers' efforts to advance bold ideas toward creating or partnering with a commercial entity.
Iroko Cardio International Sàrl announces long-term, three-year, mortality data from the Phase III, open label, multi-national study comparing high-dose bolus (HDB) dosing of AGGRASTAT(tirofiban) (25mcg/kg bolus followed by a 0.15mcg/kg/min infusion for 18-24 hours) vs. ReoPro (abciximab) in patients undergoing primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI), presented at the 2010 European Society of Cardiology Meeting in Stockholm, Sweden.
A metabolic imbalance in some cancer patients following treatment with a checkpoint inhibitor drug, nivolumab, is associated with resistance to the immunotherapy agent and shorter survival, report scientists from Dana-Farber Cancer Institute, in collaborative work with the Broad Institute of MIT and Harvard.
Mice exposed to stress in the womb and soon after birth can expect a lifetime of immune system deficiencies that hinder the ability to ward off infections and cancer, Yale University researchers report March 5 in the journal Cell.
Novartis announced today new results for Cosentyx® (secukinumab) showing no further progression in joint damage in 84% of patients with psoriatic arthritis (PsA). In addition, Cosentyx maintained a treatment response in joint and skin disease, physical function and quality of life in patients over two years of treatment. These results from the extension phase of the FUTURE 1 study were presented at the 2015 Annual Meeting of the American College of Rheumatology (ACR) in San Francisco, United States.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ellen Ruth Sher, MD Po Box 603725, Charlotte, NC 28260-3725 Ph: (828) 575-2625 | Dr Ellen Ruth Sher, MD 802 W Park Ave, Suite 213, Ocean, NJ 07712-8527 Ph: (732) 695-2555 |
News Archive
Fred Hutchinson Cancer Research Center announced its first-ever grants from its newly established Evergreen Fund to spur researchers' efforts to advance bold ideas toward creating or partnering with a commercial entity.
Iroko Cardio International Sàrl announces long-term, three-year, mortality data from the Phase III, open label, multi-national study comparing high-dose bolus (HDB) dosing of AGGRASTAT(tirofiban) (25mcg/kg bolus followed by a 0.15mcg/kg/min infusion for 18-24 hours) vs. ReoPro (abciximab) in patients undergoing primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI), presented at the 2010 European Society of Cardiology Meeting in Stockholm, Sweden.
A metabolic imbalance in some cancer patients following treatment with a checkpoint inhibitor drug, nivolumab, is associated with resistance to the immunotherapy agent and shorter survival, report scientists from Dana-Farber Cancer Institute, in collaborative work with the Broad Institute of MIT and Harvard.
Mice exposed to stress in the womb and soon after birth can expect a lifetime of immune system deficiencies that hinder the ability to ward off infections and cancer, Yale University researchers report March 5 in the journal Cell.
Novartis announced today new results for Cosentyx® (secukinumab) showing no further progression in joint damage in 84% of patients with psoriatic arthritis (PsA). In addition, Cosentyx maintained a treatment response in joint and skin disease, physical function and quality of life in patients over two years of treatment. These results from the extension phase of the FUTURE 1 study were presented at the 2015 Annual Meeting of the American College of Rheumatology (ACR) in San Francisco, United States.
› Verified 2 days ago
Dr. Jacqueline Ross, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 802 W Park Ave, Suite 213, Ocean, NJ 07712 Phone: 732-695-2555 Fax: 732-695-2552 | |
Dr. Gary Lance Gross, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 802 W Park Ave, Ste 213, Ocean, NJ 07712 Phone: 732-695-2555 Fax: 732-695-2552 |